Hormone Replacement Therapy Market to Reach $35.4 Billion by 2035

Hormone replacement therapy (HRT) market was valued at $19.2 billion in 2025 and is projected to reach $35.4 billion by 2035, growing at a CAGR of 6.2% during the forecast period (2026–2035). The increasing prevalence of menopause-related disorders, hormonal deficiencies, thyroid disorders, and age-associated endocrine conditions is significantly driving demand for hormone replacement therapies globally. Rising awareness regarding women’s health, expanding access to menopause management therapies, and growing adoption of personalized hormonal treatments are accelerating market growth across developed and emerging healthcare systems.

Browse the full report description of “Hormone Replacement Therapy Market Size, Share & Trends Analysis Report, By Therapy Type ( Estrogen Replacement Therapy (ERT), Combined Estrogen-Progesterone Therapy (EPT), Testosterone Replacement Therapy (TRT), Growth Hormone Replacement Therapy, Thyroid Hormone Replacement Therapy, Bioidentical Hormone Replacement Therapy), By Route of Administration (Oral, Transdermal, Injectable, Vaginal, and Implantable), By Indication (Menopause Management, Hypogonadism, Growth Hormone Deficiency, Thyroid Disorders, Osteoporosis Prevention, Gender Transition Therapy, Infertility & Reproductive Disorders, Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/hormone-replacement-therapy-market

Healthcare providers are increasingly recommending hormone replacement therapies to improve quality of life, manage vasomotor symptoms, prevent osteoporosis, and address reproductive health complications. In addition, advancements in bioidentical hormone formulations, transdermal delivery technologies, and long-acting injectable therapies are strengthening treatment adherence and patient outcomes. Growing acceptance of gender transition therapies and rising diagnoses of hypogonadism and growth hormone deficiencies are further expanding the application scope of hormone replacement therapy worldwide.

Rising Menopause Population and Healthcare Initiatives Accelerating Market Growth

The growing aging female population and increasing awareness of menopause-related healthcare needs are creating strong demand for hormone replacement therapies. According to the Scottish Health Survey 2024 published by the Scottish Government, nearly 72% of women aged 45–55 experienced menopause or perimenopause symptoms during the previous 12 months, while hormone replacement therapy was among the most commonly adopted symptom management approaches.  Similarly, the NHS Business Services Authority reported in October 2024 that approximately 13 million HRT prescription items were dispensed in England during 2023/24, reflecting a 22% increase compared with the previous year. The estimated number of patients receiving HRT also increased by 12% year-over-year, reaching approximately 2.6 million individuals.

Governments and healthcare organizations are increasingly implementing workplace wellness policies, menopause awareness programs, and women’s healthcare initiatives to improve treatment accessibility. The NHS in the UK has expanded menopause support programs and workplace guidance initiatives to improve healthcare access and employee retention among menopausal women. These developments are contributing to higher adoption rates of estrogen replacement therapies, combined estrogen-progesterone therapies, and transdermal hormone delivery systems, directly supporting long-term growth of the hormone replacement therapy market.

Expanding Endocrine Care and Personalized Treatment Demand Supporting Market Expansion

The increasing prevalence of endocrine disorders and hormone deficiencies is further strengthening demand for advanced hormone replacement therapies. Rising cases of thyroid disorders, testosterone deficiency, infertility-related hormonal imbalance, and growth hormone deficiency are encouraging healthcare providers to adopt long-term hormone management strategies. Pharmaceutical manufacturers are increasingly focusing on personalized hormone therapies, bioidentical formulations, and patient-centric drug delivery systems to improve therapeutic efficacy and reduce adverse effects. In addition, telehealth-based menopause consultation services and digital healthcare platforms are improving patient access to hormone therapies, particularly in North America and Europe. The growing availability of oral, injectable, vaginal, and implantable therapies is enabling broader treatment accessibility across multiple patient groups.

Innovation Leaders Transforming the Hormone Replacement Therapy Market

The key players operating in the hormone replacement therapy market include Novo Nordisk A/S, Merck KGaA, Bayer AG, Eli Lilly and Company, and Pfizer Inc., among others. These companies are actively investing in advanced hormonal therapies, women’s health research, bioidentical hormone formulations, and endocrine disorder management solutions to strengthen their market position globally.

• In March 2026, Sun Pharmaceutical Industries Limited expanded its metabolic and endocrine care portfolio by launching semaglutide injections under the brands Noveltreat and Sematrinity in India. The company introduced affordable GLP-1 therapies for chronic weight management and type 2 diabetes, supported by advanced prefilled pen technology and patient support programs.
• In September 2025, Eli Lilly and Company expanded its biotechnology innovation network by opening a new Lilly Gateway Labs facility in San Diego to accelerate next-generation therapeutic development. The initiative strengthens Lilly’s research ecosystem by supporting early-stage biotech firms with advanced laboratory infrastructure and scientific collaboration opportunities. This expansion reinforces the company’s long-term focus on advancing innovative therapies across endocrine and immune-related disorders, including hormone replacement treatment areas.

Market Coverage

• The market number available for – 2025–2035
• Base year – 2025
• Forecast period – 2026–2035
• Segment Covered –
• By Therapy Type
• By Route of Administration
• By Indication
• Competitive Landscape – Novo Nordisk A/S, Merck KGaA, Bayer AG, Eli Lilly and Company, and Pfizer Inc., among

Key Questions Addressed by the Report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Hormone Replacement Therapy Market Segment

By Therapy Type

• Estrogen Replacement Therapy (ERT)
• Combined Estrogen-Progesterone Therapy (EPT)
• Testosterone Replacement Therapy (TRT)
• Growth Hormone Replacement Therapy
• Thyroid Hormone Replacement Therapy
• Bioidentical Hormone Replacement Therapy

By Route of Administration

• Oral
• Transdermal
• Injectable
• Vaginal
• Implantable

By Indication

• Menopause Management
• Hypogonadism
• Growth Hormone Deficiency
• Thyroid Disorders
• Osteoporosis Prevention
• Gender Transition Therapy
• Infertility & Reproductive Disorders

Global Hormone Replacement Therapy Market Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• France
• Italy
• Spain
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/hormone-replacement-therapy-market